282 related articles for article (PubMed ID: 8847891)
1. The use of lipid formulations of amphotericin B for systemic fungal infections.
Leenders AC; de Marie S
Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
[TBL] [Abstract][Full Text] [Related]
2. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
4. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
5. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
6. The current role of amphotericin B lipid complex in managing systemic fungal infections.
Chu P; Sadullah S
Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
[TBL] [Abstract][Full Text] [Related]
7. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
8. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
9. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
12. Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent?
Cifani C; Costantino S; Massi M; Berrino L
Acta Biomed; 2012 Aug; 83(2):154-63. PubMed ID: 23393924
[TBL] [Abstract][Full Text] [Related]
13. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
14. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212
[TBL] [Abstract][Full Text] [Related]
15. Optimizing efficacy of amphotericin B through nanomodification.
Vyas SP; Gupta S
Int J Nanomedicine; 2006; 1(4):417-32. PubMed ID: 17722276
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
17. The role of liposomal amphotericin B in the treatment of systemic fungal infections.
Patterson TF; Andriole VT
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S63-8. PubMed ID: 2693111
[TBL] [Abstract][Full Text] [Related]
18. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
